|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
71203-35-5
|
|
gptkbp:clinicalTrialPhase
|
Phase II
|
|
gptkbp:developedBy
|
cyclin-dependent kinase inhibitor
|
|
gptkbp:discoveredBy
|
gptkb:Sanofi
|
|
gptkbp:hasInChIKey
|
QBUVFDKTZJNUPP-IBGZPJMESA-N
|
|
gptkbp:hasMolecularFormula
|
C21H23N3O4
|
|
gptkbp:hasSMILES
|
CN1CC[C@@H](C1N(C)C2=CC(=C(C=C2OC)C(=O)N)C)C(=O)N
|
|
gptkbp:hasUNII
|
8N3DW7272P
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alvocidib
|
|
gptkbp:is_investigational_drug
|
true
|
|
gptkbp:IUPACName
|
(2S)-2-[(3S,4R)-3-hydroxy-1-methyl-4-(methylamino)pyrrolidin-1-yl]-8-methoxy-5-methyl-7-oxo-1,2,3,4-tetrahydroquinoline-6-carboxamide
|
|
gptkbp:mechanismOfAction
|
CDK inhibitor
|
|
gptkbp:meltingPoint
|
246-248°C
|
|
gptkbp:molecularWeight
|
381.43 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL297
DB01205
5287969
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:synonym
|
NSC 649890
Flavopiridol
L-868275
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
chronic lymphocytic leukemia
|
|
gptkbp:bfsParent
|
gptkb:Servier_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|